EML4 and digestive system neoplasm: Both crizotinib and entrectinib inhibited the phosphorylation of ALK and its downstream signal molecules, including ERK1/2 and AKT from this EML4-ALK rearranged colon patient tumor derived cell line (Figure 3E).